The Hyderabad-based company has stopped the production, distribution and marketing of the drug and is in the process of recalling stocks, a company spokesperson told Business Line.
“The product has passed all quality tests. However, on DCGI’s instructions, we have stopped marketing the product in the interim.”
“We are taking immediate steps to investigate the issue,” he said.
Testing Procedures
The testing procedures for the drug should also be looked into as Albupax was nanotechnology-based products.
“The testing procedures for this drug are quite complex,” he added.
Natco is currently engaged in a legal dispute on patent of Albupax with its original innovator, American Biosciences and is awaiting judgment.
It had launched the product in the domestic market in September 2008, at Rs 11,000 a tablet and recently tied up with Dr Reddy’s Laboratories for marketing the drug in the US.
The recall would not impact the company’s revenue as they were insignificant, he said.
He added that, “We just have 15 patients in the country who are using the drug.”
Business Line
18 July 2009
Hyderabad, India
Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.
